Nifty
Sensex
:
:
11196.50
37892.36
101.25 (0.91%)
204.45 (0.54%)

Pharmaceuticals & Drugs - API

Rating :
81/99

BSE: 532482 | NSE: GRANULES

302.60
04-Aug-2020
  • Open
  • High
  • Low
  • Previous Close
  •  301.00
  •  309.45
  •  296.85
  •  299.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5707076
  •  17318.09
  •  310.95
  •  86.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,475.76
  • 20.56
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 8,083.92
  • 0.33%
  • 3.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 42.13%
  • 5.30%
  • 23.53%
  • FII
  • DII
  • Others
  • 22.95%
  • 0.10%
  • 5.99%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.52
  • 13.87
  • 15.54

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.03
  • 13.75
  • 13.54

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.95
  • 19.93
  • 38.52

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.28
  • 17.76
  • 14.89

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.75
  • 3.04
  • 2.10

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.26
  • 10.59
  • 9.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
735.60
595.27
23.57%
599.88
613.32
-2.19%
703.96
631.78
11.42%
699.53
580.87
20.43%
Expenses
552.01
476.65
15.81%
499.94
515.71
-3.06%
540.81
518.48
4.31%
555.93
480.34
15.74%
EBITDA
183.59
118.62
54.77%
99.95
97.61
2.40%
163.15
113.30
44.00%
143.60
100.53
42.84%
EBIDTM
24.96%
19.93%
16.66%
15.91%
23.18%
17.93%
20.53%
17.31%
Other Income
5.63
1.86
202.69%
22.52
1.88
1,097.87%
3.51
5.88
-40.31%
8.67
4.18
107.42%
Interest
5.95
6.87
-13.39%
6.57
6.85
-4.09%
6.73
7.47
-9.91%
6.85
7.60
-9.87%
Depreciation
34.08
28.67
18.87%
38.97
27.42
42.12%
38.99
27.01
44.35%
30.32
26.53
14.29%
PBT
149.19
84.94
75.64%
136.70
65.22
109.60%
88.90
84.69
4.97%
115.10
70.59
63.05%
Tax
37.74
27.19
38.80%
44.36
20.18
119.82%
24.87
26.46
-6.01%
19.31
23.35
-17.30%
PAT
111.45
57.75
92.99%
92.34
45.04
105.02%
64.03
58.23
9.96%
95.79
47.23
102.82%
PATM
15.15%
9.70%
15.39%
7.34%
9.10%
9.22%
13.69%
8.13%
EPS
4.51
2.34
92.74%
3.74
1.82
105.49%
2.59
2.36
9.75%
3.88
1.91
103.14%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
2,738.97
2,598.65
2,279.20
1,684.62
1,410.57
1,357.18
1,292.92
1,095.86
764.37
653.97
475.18
Net Sales Growth
13.12%
14.02%
35.29%
19.43%
3.93%
4.97%
17.98%
43.37%
16.88%
37.63%
 
Cost Of Goods Sold
1,283.08
1,280.93
1,255.56
896.32
679.63
725.03
746.95
645.25
466.92
414.36
295.55
Gross Profit
1,455.89
1,317.72
1,023.64
788.30
730.93
632.15
545.97
450.61
297.45
239.60
179.63
GP Margin
53.15%
50.71%
44.91%
46.79%
51.82%
46.58%
42.23%
41.12%
38.91%
36.64%
37.80%
Total Expenditure
2,148.69
2,073.33
1,895.16
1,406.20
1,111.73
1,081.29
1,084.31
937.57
679.35
574.68
418.92
Power & Fuel Cost
-
59.74
57.67
48.22
38.67
34.97
45.73
36.70
37.71
26.28
23.07
% Of Sales
-
2.30%
2.53%
2.86%
2.74%
2.58%
3.54%
3.35%
4.93%
4.02%
4.86%
Employee Cost
-
259.04
209.82
165.21
140.19
117.57
106.96
85.84
59.71
45.46
33.38
% Of Sales
-
9.97%
9.21%
9.81%
9.94%
8.66%
8.27%
7.83%
7.81%
6.95%
7.02%
Manufacturing Exp.
-
177.94
157.62
120.84
88.60
66.97
50.89
38.68
24.34
18.90
14.71
% Of Sales
-
6.85%
6.92%
7.17%
6.28%
4.93%
3.94%
3.53%
3.18%
2.89%
3.10%
General & Admin Exp.
-
125.63
99.96
83.05
67.65
60.38
59.84
44.42
26.96
21.31
16.52
% Of Sales
-
4.83%
4.39%
4.93%
4.80%
4.45%
4.63%
4.05%
3.53%
3.26%
3.48%
Selling & Distn. Exp.
-
112.17
91.84
83.08
81.37
67.75
71.70
85.04
61.70
47.62
32.32
% Of Sales
-
4.32%
4.03%
4.93%
5.77%
4.99%
5.55%
7.76%
8.07%
7.28%
6.80%
Miscellaneous Exp.
-
57.88
22.69
9.49
15.61
8.62
2.24
1.64
2.01
0.74
32.32
% Of Sales
-
2.23%
1.00%
0.56%
1.11%
0.64%
0.17%
0.15%
0.26%
0.11%
0.71%
EBITDA
590.29
525.32
384.04
278.42
298.84
275.89
208.61
158.29
85.02
79.29
56.26
EBITDA Margin
21.55%
20.22%
16.85%
16.53%
21.19%
20.33%
16.13%
14.44%
11.12%
12.12%
11.84%
Other Income
40.33
36.56
26.68
10.84
9.93
5.62
4.34
4.31
2.06
1.38
0.80
Interest
26.10
27.02
28.46
33.06
32.26
37.07
32.35
20.43
17.67
16.99
11.99
Depreciation
142.36
136.95
105.48
76.20
71.51
58.40
52.65
29.81
23.08
20.70
18.31
PBT
489.89
397.90
276.78
180.00
204.99
186.03
127.96
112.36
46.32
42.98
26.76
Tax
126.28
115.73
89.11
63.40
65.20
61.15
37.05
37.13
13.76
13.02
5.86
Tax Rate
25.78%
27.19%
32.20%
35.22%
31.81%
32.87%
28.95%
33.05%
29.71%
30.29%
21.90%
PAT
363.61
309.91
187.67
116.60
139.79
124.89
90.91
75.23
32.57
29.95
20.90
PAT before Minority Interest
363.61
309.91
187.67
116.60
139.79
124.89
90.91
75.23
32.57
29.95
20.90
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
13.28%
11.93%
8.23%
6.92%
9.91%
9.20%
7.03%
6.86%
4.26%
4.58%
4.40%
PAT Growth
74.60%
65.14%
60.95%
-16.59%
11.93%
37.38%
20.84%
130.98%
8.75%
43.30%
 
EPS
14.72
12.54
7.59
4.72
5.66
5.05
3.68
3.04
1.32
1.21
0.85

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
1,843.72
1,529.47
1,304.18
903.60
661.60
431.16
355.96
274.85
245.09
219.78
Share Capital
25.42
25.42
25.38
22.87
21.67
20.43
20.28
20.13
20.06
20.06
Total Reserves
1,800.02
1,493.09
1,273.38
878.28
611.13
410.74
335.43
254.41
225.03
199.72
Non-Current Liabilities
485.98
552.63
488.19
187.99
246.62
356.52
343.51
202.00
112.60
58.88
Secured Loans
414.83
478.78
433.13
123.90
183.66
302.59
295.86
174.85
87.30
37.08
Unsecured Loans
6.69
0.00
0.00
0.34
0.55
0.62
13.38
0.65
0.75
0.75
Long Term Provisions
21.50
12.58
7.70
7.25
5.58
4.03
3.97
2.04
1.53
1.19
Current Liabilities
966.54
896.48
877.91
787.13
654.75
415.03
292.54
205.78
213.63
157.11
Trade Payables
430.02
323.48
274.35
215.98
181.10
187.63
135.54
91.84
75.52
51.81
Other Current Liabilities
153.16
113.60
69.84
93.43
79.21
88.98
47.78
23.77
31.39
18.65
Short Term Borrowings
371.69
454.21
525.10
473.83
392.85
124.97
100.91
85.46
102.06
83.15
Short Term Provisions
11.66
5.20
8.62
3.90
1.58
13.45
8.30
4.71
4.66
3.50
Total Liabilities
3,296.24
2,978.58
2,670.28
1,878.72
1,562.97
1,202.71
992.01
682.63
571.32
435.77
Net Block
1,203.97
944.25
776.73
644.34
559.94
616.55
482.47
263.46
250.42
238.62
Gross Block
1,875.23
1,472.94
1,199.63
983.66
822.98
843.76
653.90
387.41
354.50
322.61
Accumulated Depreciation
671.26
528.69
422.90
339.32
263.05
227.21
171.43
123.95
104.07
83.99
Non Current Assets
1,594.41
1,696.34
1,483.71
1,050.55
744.97
699.69
611.55
388.87
310.52
256.75
Capital Work in Progress
294.20
495.95
514.52
267.43
76.56
62.03
124.56
108.80
29.30
6.85
Non Current Investment
19.34
210.42
156.56
108.23
70.11
0.19
0.19
0.19
0.19
0.30
Long Term Loans & Adv.
76.89
45.72
35.91
30.56
38.37
20.76
4.33
16.42
30.50
10.71
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.15
0.00
0.00
0.12
0.27
Current Assets
1,701.84
1,282.24
1,186.57
828.16
818.00
500.36
376.92
288.88
260.26
179.02
Current Investments
109.85
0.00
0.00
0.00
0.00
0.00
0.00
9.46
0.00
0.00
Inventories
438.43
384.21
279.95
269.18
253.72
224.52
174.16
136.48
109.91
75.13
Sundry Debtors
735.18
673.54
628.25
417.70
375.35
136.91
110.91
71.02
95.01
71.61
Cash & Bank
283.94
89.04
115.64
49.80
130.29
65.31
41.75
41.71
31.98
11.99
Other Current Assets
134.43
36.99
48.64
39.83
58.65
73.63
50.10
30.21
23.36
20.29
Short Term Loans & Adv.
91.83
98.46
114.09
51.66
48.68
2.05
28.76
16.93
13.18
12.28
Net Current Assets
735.30
385.76
308.65
41.03
163.25
85.33
84.38
83.09
46.63
21.91
Total Assets
3,296.25
2,978.58
2,670.28
1,878.71
1,562.97
1,202.72
992.01
682.64
571.31
435.77

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
476.19
262.24
-0.65
188.24
151.43
150.28
107.95
91.18
25.60
48.56
PBT
425.64
276.78
180.00
204.99
186.03
127.96
112.36
46.32
42.98
26.76
Adjustment
156.88
149.85
107.45
95.14
92.63
85.37
50.39
41.46
37.74
33.11
Changes in Working Capital
12.75
-75.94
-230.03
-52.37
-79.70
-31.34
-31.03
14.60
-43.61
-5.70
Cash after chg. in Working capital
595.27
350.69
57.42
247.77
198.97
182.00
131.73
102.39
37.11
54.16
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-119.08
-88.45
-58.07
-59.53
-47.54
-31.72
-23.78
-11.20
-11.51
-5.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-160.63
-269.82
-462.31
-326.09
-161.65
-145.55
-254.63
-127.79
-54.47
-25.09
Net Fixed Assets
-124.57
-176.36
-282.01
-249.86
-75.62
-231.53
-64.60
-89.18
-54.67
-23.22
Net Investments
-48.78
-431.34
-0.01
13.84
-16.48
72.98
-94.69
-17.96
-10.20
0.00
Others
12.72
337.88
-180.29
-90.07
-69.55
13.00
-95.34
-20.65
10.40
-1.87
Cash from Financing Activity
-212.85
-17.43
528.62
55.87
85.67
18.83
146.72
46.33
48.86
-24.96
Net Cash Inflow / Outflow
102.70
-25.01
65.66
-81.98
75.44
23.56
0.04
9.72
19.99
-1.49
Opening Cash & Equivalents
83.02
108.03
42.37
124.35
54.85
41.75
41.71
31.98
11.99
13.47
Closing Cash & Equivalent
185.93
83.02
108.03
42.37
130.29
65.31
41.75
41.71
31.98
11.99

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
71.80
59.73
51.17
39.40
29.20
20.98
17.36
13.40
12.19
10.96
ROA
9.88%
6.64%
5.13%
8.12%
9.03%
8.31%
8.98%
5.19%
5.95%
4.91%
ROE
18.54%
13.32%
10.60%
18.23%
23.53%
23.29%
24.20%
12.67%
12.90%
9.98%
ROCE
17.22%
12.71%
11.09%
16.57%
20.16%
18.75%
19.90%
12.95%
14.89%
11.00%
Fixed Asset Turnover
1.75
1.71
1.55
1.59
1.66
1.77
2.14
2.11
1.96
1.54
Receivable days
87.91
104.24
112.83
100.84
67.60
33.47
29.73
38.66
45.82
52.00
Inventory Days
51.34
53.18
59.23
66.49
63.11
54.79
50.77
57.37
50.89
54.38
Payable days
64.46
54.96
62.37
64.87
59.99
53.57
43.67
44.19
40.05
38.81
Cash Conversion Cycle
74.78
102.46
109.70
102.46
70.72
34.69
36.83
51.84
56.66
67.57
Total Debt/Equity
0.49
0.65
0.75
0.73
1.01
1.14
1.25
1.00
0.83
0.63
Interest Cover
16.75
10.72
6.44
7.36
6.02
4.96
6.50
3.62
3.53
3.23

News Update:


  • Granules India’s arm voluntarily recalls Metformin Hydrochloride Extended-Release Tablets
    3rd Jul 2020, 10:44 AM

    Granules’ test results showed NDMA levels above the FDA acceptable limit in 1 out of the 12 batches distributed to the US market

    Read More
  • Granules India’s arm gets USFDA’s nod for Vigabatrin for Oral Solution
    27th Apr 2020, 09:07 AM

    It is bioequivalent to the reference listed drug product, Sabril for Oral Solution, 500 mg, of Lundbeck Pharmaceuticals LLC

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.